Medivation (MDVN) PT Lifted to $53 at BMO Capital

August 10, 2016 7:10 AM EDT
Get Alerts MDVN Hot Sheet
Price: $81.44 --0%

Rating Summary:
    14 Buy, 18 Hold, 1 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 17 | Down: 27 | New: 7
Trade MDVN Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

BMO Capital analyst Do Kim raised estimates and its price target on Medivation (NASDAQ: MDVN) to $53.00 but maintained a Market Perform rating.

Kim commented, :We are incrementally more positive on MDVN following 2Q16 earnings, as underlying Xtandi trends improve, particularly treatment duration as the drug gains first novel hormone therapy (NHT) share over Zytiga. We are increasing our Xtandi sales projections, with updated duration assumptions. While our target price increases to $53, it remains below market as we believe shares reflect an acquisition premium above our DCF valuation. We continue to look towards the Xtandi label update (Oct 22, 2016 PDUFA) as a catalyst to reaccelerate adoption, moving Xtandi upstream to Casodex-eligible patients, and an opportunity for us to become more positive on the shares. Additional upside to our Market Perform rating includes pending talazoparib data (4Q16), which contributed to significant revaluation of talazoparib’s contingent consideration. We believe talazoparib could be the primary disconnect with bidders if the acquisition fails, as MDVN continues to emphasize a large opportunity for the PARP inhibitor,:

For an analyst ratings summary and ratings history on Medivation click here. For more ratings news on Medivation click here.

Shares of Medivation closed at $63.45 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

BMO Capital, Raising Prices, Earnings, Definitive Agreement, PDUFA

Add Your Comment